What is the 13F Pro Quality Score for SCLX?

13F Pro ranks Scilex Holding Co (SCLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SCLX's current score at https://13fpro.ai/company/SCLX (free sign-up required for the full ranking).

Which hedge funds own the most SCLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SCLX include VANGUARD CAPITAL MANAGEMENT, BlackRock,, VANGUARD FIDUCIARY CO. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SCLX as soon as new 13F filings post.

Where does 13F Pro source SCLX data?

All Scilex Holding Co fundamentals and ownership data come directly from SEC EDGAR. Scilex Holding Co files with the SEC under CIK 1820190. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SCLX in?

Scilex Holding Co (SCLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SCLX research updated on 13F Pro?

SCLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Scilex Holding Co(SCLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1820190 SCLX stock profile & AI dashboard →

13F Pro Quality Score

9.1/100

Rank #2,923 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

3.6/100

Profitability

2.0/100

Balance Sheet

0.2/100

Earnings Quality

46.5/100

Free Cash Flow

9.0/100

Institutional Flow

15.4/100

Revenue Scale

5.6/100

Dilution Risk

4.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SCLX Scores 9/100

exact factor attribution · 2026-09-11

SCLX's composite is held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

-0.3 pts

47th pct

Institutional flow

-1.7 pts

15th pct

Shareholder dilution

-2.3 pts

5th pct

Earnings growth

-2.3 pts

4th pct

Capital efficiency

-5.0 pts

0th pct

Free cash flow

-6.2 pts

9th pct

Scale

-6.7 pts

6th pct

Profitability

-7.2 pts

2th pct

Revenue growth

-9.3 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SCLX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Scilex Holding Co (SCLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SCLX at 9.1/100 on a 32-signal composite quality model, placing it at rank #2,923 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (0.2) and profitability (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Scilex Holding Co reports quarterly revenue of $7.6M, net income of $-115.0M. Top institutional holders of SCLX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock, VANGUARD FIDUCIARY, based on the most recent SEC filings. SCLX trades on the Nasdaq exchange and files with the SEC under CIK 1820190. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scilex Holding Co directly from SEC EDGAR. Scilex Holding Co's 13F Pro composite quality score has ranged between 9 and 40 since 2023, currently 9.1 — a declining long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about Scilex Holding Co

Quirks, history, and lore behind SCLX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · focused on non-opioid pain management.
2
The Numbers
Revenues in the tens of millions of dollars annually — a commercial-stage biotech still working toward profitability in a market worth billions.
3
The History
The company traces its roots to a spin-off from Sorrento Therapeutics, going public as an independent entity in the early 2020s.
4
The Secret
Its commercial focus is a long-acting injectable local anesthetic — a product designed to keep patients comfortable for days after surgery without addictive opioids.
5
The Lore
Its lead product, ZTlido, is a lidocaine patch for post-shingles nerve pain — and the company has been building a pipeline of lidocaine-based therapies across multiple pain indications.
6
The Giveaway
Ticker SCLX, born from Sorrento, betting that non-addictive pain relief can win over a healthcare world desperate to move past the opioid crisis.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$7.6M

Net Income

Q2 2026

$-115.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-46.5% YoY

$30.3MFY 2025

FY22 $38.0MFY23 $46.7MFY24 $56.6MFY25 $30.3M

Net Income

-413.8% YoY

$-374.1MFY 2025

FY22 $-23.4MFY23 $-114.3MFY24 $-72.8MFY25 $-374.1M

Operating Income

-314.9% YoY

$-346.0MFY 2025

FY22 $-50.6MFY23 $-105.4MFY24 $-83.4MFY25 $-346.0M

EPS (Diluted)

-353.2% YoY

$-36.48FY 2025

FY22 $-0.17FY23 $-1.28FY24 $-8.05FY25 $-36.48

Total Assets

+292.7% YoY

$365.0MFY 2025

FY22 $86.5MFY23 $101.3MFY24 $93.0MFY25 $365.0M

Total Debt

+138.7% YoY

$83.3MFY 2025

FY22 $0.00FY23 $108.4MFY24 $34.9MFY25 $83.3M

Op. Cash Flow

-80.3% YoY

$3.8MFY 2025

FY22 $-21.3MFY23 $-20.7MFY24 $19.3MFY25 $3.8M

Free Cash Flow

-81.0% YoY

$3.7MFY 2025

FY22 $-21.3MFY23 $-20.7MFY24 $19.3MFY25 $3.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$30.3M -46.5%	$56.6M +21.1%	$46.7M +22.9%	$38.0M +21.4%	$31.3M +32.9%	$23.6M
Net Income	$-374.1M -413.8%	$-72.8M +36.3%	$-114.3M -389.3%	$-23.4M +73.6%	$-88.4M -86.1%	$-47.5M
Operating Income	$-346.0M -314.9%	$-83.4M +20.9%	$-105.4M -108.2%	$-50.6M -41.3%	$-35.8M -1.6%	$-35.3M
EPS (Diluted)	$-36.48 -353.2%	$-8.05 -528.9%	$-1.28 -652.9%	$-0.17 -942.9%	$-0.02 -85.2%	$-0.01
Total Assets	$365.0M +292.7%	$93.0M -8.2%	$101.3M +17.1%	$86.5M -38.2%	$139.9M +70042.6%	$199.5K
Total Debt	$83.3M +138.7%	$34.9M -67.8%	$108.4M	$0.00 -100.0%	$139.1M	—
Operating Cash Flow	$3.8M -80.3%	$19.3M +193.4%	$-20.7M +2.6%	$-21.3M +25.8%	$-28.7M +8.9%	$-31.5M
Free Cash Flow	$3.7M -81.0%	$19.3M +193.3%	$-20.7M +2.5%	$-21.3M +25.8%	$-28.7M +9.0%	$-31.5M

Get alerted when SCLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Scilex Holding Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SCLX

VANGUARD CAPITAL MANAGEMENT LLC
$2.4M301,292 sh
BlackRock, Inc.
$853.5K109,417 sh
VANGUARD FIDUCIARY TRUST CO
$357.4K45,822 sh
JACOBS LEVY EQUITY MANAGEMENT, INC
$321.1K41,163 sh
STATE STREET CORP
$275.9K35,376 sh
UBS Group AG
$260.3K33,376 sh
RENAISSANCE TECHNOLOGIES LLC
$257.9K33,064 sh
CITADEL ADVISORS LLC
$214.5K27,497 sh
PRICE T ROWE ASSOCIATES INC /MD/
$164.0K20,920 sh
Ashton Thomas Private Wealth, LLC
$144.2K18,482 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$2.4M	301,292
BlackRock, Inc.	$853.5K	109,417
VANGUARD FIDUCIARY TRUST CO	$357.4K	45,822
JACOBS LEVY EQUITY MANAGEMENT, INC	$321.1K	41,163
STATE STREET CORP	$275.9K	35,376
UBS Group AG	$260.3K	33,376
RENAISSANCE TECHNOLOGIES LLC	$257.9K	33,064
CITADEL ADVISORS LLC	$214.5K	27,497
PRICE T ROWE ASSOCIATES INC /MD/	$164.0K	20,920
Ashton Thomas Private Wealth, LLC	$144.2K	18,482

Companies Similar to SCLX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MGX

Metagenomi Therapeutics, Inc.

AI score

Similar quality profile · 1 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC

DTIL

PRECISION BIOSCIENCES INC

AI score

Similar quality profile · 1 shared holders

TSFG, LLC

CRSP

CRISPR Therapeutics AG

AI score

Similar quality profile

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 1 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC

MXCT

MAXCYTE, INC.

AI score

Similar quality profile · 1 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC

GOSS

Gossamer Bio, Inc.

AI score

Similar quality profile · 1 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC

FATE

FATE THERAPEUTICS INC

AI score

Similar quality profile

TLRY

Tilray Brands, Inc.

AI score

Similar quality profile · 8 shared holders

Spectrum Wealth Advisory Group, LLC Pacifica Partners Inc.SOA Wealth Advisors, LLC.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SCLX on your watchlist

Track score changes the day Scilex Holding Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SCLX a good stock to buy?

13F Pro's AI-powered analysis of Scilex Holding Co (SCLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCLX are available on the SCLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SCLX is classified as a small company.

Which hedge funds own SCLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Scilex Holding Co's investment landscape.